European Journal of Medicinal Chemistry Reports, published by ELSEVIER, is a vital platform dedicated to advancing the field of medicinal chemistry through open access communication of high-quality research. With an impact factor reflecting its growing influence, this journal has rapidly established a reputation for scholarly excellence since its launch in 2021. It serves as a converging point for innovative studies and reviews that span the disciplines of chemistry and molecular medicine, reflected in its Q2 and Q3 quartile rankings in relevant categories for 2023. Situated in France, the journal is accessible globally, ensuring that researchers, professionals, and students can easily engage with significant findings and methodologies in medicinal chemistry. The open access model facilitates the dissemination of knowledge, bridging gaps between laboratory research and practical applications in drug development. By fostering collaboration and highlighting emerging trends, the European Journal of Medicinal Chemistry Reports plays a crucial role in shaping the future of therapeutic innovations.

European Journal of Medicinal Chemistry, a premier publication by Elsevier France-Editions Scientifiques Médicales Elsevier, has been at the forefront of advancing medicinal chemistry since its inception in 1974. With an impressive impact factor and ranking in the Q1 quartile across multiple categories including Drug Discovery, Medicine (miscellaneous), Organic Chemistry, and Pharmacology, this journal delivers cutting-edge research and reviews that are vital for researchers and professionals in the field. The journal’s scope encompasses the design, synthesis, and evaluation of biological activity of bioactive compounds, making it a critical resource for those looking to innovate in drug development and therapeutic strategies. Although currently not open access, subscribers can benefit from its diverse range of high-quality articles, ensuring the dissemination of knowledge in the ever-evolving landscape of medicinal chemistry. The European Journal of Medicinal Chemistry continues to play a pivotal role in shaping the future of pharmacological research and its application, thus appealing to an audience dedicated to making impactful scientific contributions.

Chemical Biology Letters is a prominent academic journal dedicated to the evolving field of biochemistry and its applications in medical and clinical contexts. Published by ScienceIn Publications, this journal serves as a vital platform for researchers, professionals, and students alike, showcasing cutting-edge findings and innovations that drive forward our understanding of chemical interactions in biological systems. With its scope ranging from molecular biology to clinical biochemistry, Chemical Biology Letters is committed to advancing knowledge and fostering collaboration within the scientific community. Recognized for its quality, the journal is categorized in Q4 for Biochemistry and Molecular Biology fields, while achieving notably higher ranks in Medical Biochemistry, reflecting its significant contributions to the discipline. Aiming to remain accessible to a diverse audience, the journal is published in open access format, inviting researchers worldwide to explore and share invaluable insights. Established in 2014, it continues to grow in impact and relevance, paving the way for advancements in both theoretical and applied research within the realm of chemical biology.

Chemical Biology & Drug Design, an esteemed publication by WILEY, serves as a vital platform for the dissemination of pioneering research in the interdisciplinary fields of biochemistry, drug discovery, molecular medicine, organic chemistry, and pharmacology. With a dedicated commitment to advancing the understanding of chemical interactions and drug development, this journal not only fosters innovation but also bridges the gap between theoretical research and practical applications. It boasts an impressive impact factor and is recognized in the 2023 category quartiles as Q3 in Biochemistry and Molecular Medicine, and Q2 in Drug Discovery, Organic Chemistry, and Pharmacology, indicating its relevance and influence in these crucial areas. The journal’s rankings across various Scopus categories further solidify its position as a reputable resource for researchers, professionals, and students striving to stay at the forefront of medicinal chemistry and drug design. While primarily traditional access-based, the journal's evolving scope from 2006 to 2024 ensures an ongoing contribution to essential scientific dialogue, making it an indispensable read for those committed to advancing health sciences.

Computational Toxicology is a premier journal published by Elsevier, dedicated to advancing the field of computational approaches in toxicological research. With an ISSN of 2468-1113, this journal provides a platform for researchers and professionals to share their innovative studies and methodologies from 2017 through 2024, promoting insightful discourse in essential areas such as computer science applications and toxicology. Recognized for its rigor and impact, it currently holds a Q2 ranking across various categories, including Computer Science Applications, Health, Toxicology and Mutagenesis, and Toxicology, highlighting its significance in the academic community. The journal is indexed in Scopus, boasting notable ranks including #284/817 in Computer Science Applications and #58/148 in Health, Toxicology and Mutagenesis, demonstrating its vital contribution to addressing contemporary challenges in environmental health and pharmacology. While it is not an open access journal, Computational Toxicology offers valuable insights for students, researchers, and practitioners striving to leverage computational frameworks to enhance the safety and efficacy of substances in human health and the environment.

Letters in Drug Design & Discovery is an esteemed journal dedicated to advancing the fields of Drug Discovery and Molecular Medicine. Published by Bentham Science Publishers, this journal offers a platform for the dissemination of innovative research and advanced methodologies, enhancing collaboration among researchers and professionals in pharmaceutical sciences. Despite its current Q4 ranking in Drug Discovery and Molecular Medicine and Q3 in Pharmaceutical Science for 2023, the journal is committed to improving its presence in the academic community by providing quality, peer-reviewed publications that cover various aspects of drug design and discovery, including novel therapeutic approaches and methodologies. With a focus on both foundational and cutting-edge research from around the globe, Letters in Drug Design & Discovery is pivotal for those seeking to stay abreast of developments in drug development and molecular research. Researchers are encouraged to submit their work, engage with the burgeoning field, and contribute to the ongoing dialogue driven by this journal, which spans the years from 2005 to 2024. While the journal does not currently offer open access, its contributions remain accessible to a wide range of academic and professional audiences.

Chemical Research in Toxicology is a premier journal published by the American Chemical Society, dedicated to advancing the understanding of toxicological effects associated with chemical substances. Since its inception in 1988, this esteemed journal has maintained a robust impact factor, ranking in the Q1 quartile for both Medicine (miscellaneous) and Toxicology as of 2023, reflecting its significance and influence in the fields of pharmacology and toxicology. With an impressive Scopus ranking at #16 out of 133 in the Toxicology category, it serves as a vital resource for researchers, professionals, and students seeking cutting-edge insights and scholarly articles that bridge the gap between chemistry and toxicological science. Although not an open-access publication, it continues to provide comprehensive analyses and original research that inform safe chemical practices and regulatory policies, further enhancing its role in public health and safety.

ARCHIVES OF TOXICOLOGY is a prestigious journal published by Springer Heidelberg, dedicated to advancing research in the field of toxicology and related disciplines. With a distinguished history dating back to 1930, this journal has continuously provided vital insights and groundbreaking studies, making it a cornerstone in the areas of health, toxicology, and medicine. Recognized for its high impact, it occupies a top-ranking position in Scopus, with remarkable quartile placements in 2023, categorizing it as Q1 in Health, Toxicology and Mutagenesis, and Q1 in Medicine (Miscellaneous). The journal highlights critical research and innovative methodologies, appealing to a diverse audience of researchers, professionals, and students committed to understanding the complexities of toxic substances and their implications for public health and environmental safety. The journal does not currently offer open access, allowing for a more traditional but rigorous peer-review process that ensures the quality and integrity of every published article. Join the global discourse in toxicological science with ARCHIVES OF TOXICOLOGY, where every contribution furthers the understanding of safety and toxicity in our world.

Drug and Chemical Toxicology is a well-respected journal in the fields of toxicology, pharmacology, and public health, published by Taylor & Francis Ltd. Since its inception in 1978, this journal has diligently explored the effects and mechanisms of chemical exposures on health and the environment, fulfilling a crucial role in advancing scientific understanding and safeguarding public health. The journal is indexed across prestigious databases and features an impressive array of articles categorized within the Q2 and Q3 quartiles across various categories in 2023, reflecting its significance in Chemical Health and Safety as well as Environmental and Occupational Health disciplines. With an extensive reach and a focus on interdisciplinary research, Drug and Chemical Toxicology offers a rich repository of original research, reviews, and methodological advancements, catering to a diverse audience of researchers, professionals, and students dedicated to the betterment of safety and health standards. Although not an open-access publication, its articles are widely accessible to the academic community, ensuring that critical innovations and insights are shared for the greater good.

TOXICOLOGY LETTERS is a prominent journal dedicated to advancing the field of toxicology, providing a platform for high-quality research and reviews that explore the effects of chemical substances on biological systems. Published by Elsevier Ireland Ltd, this peer-reviewed journal has established itself as a vital resource in toxicological research since its inception in 1977, with a convergence of studies extending to 2024. With an impressive Scopus ranking, positioned at #28 out of 133 in the Toxicology category, TOXICOLOGY LETTERS garners a respectable percentile of 79, highlighting its significance in the academic community. Although it is not an open-access journal, its research is accessible through institutional subscriptions, ensuring that critical insights into human health and environmental safety are disseminated effectively. Being categorized in the Q2 quartile in both Medicine (miscellaneous) and Toxicology for 2023 further emphasizes its relevance and impact in these fields. This journal aims to foster collaboration between researchers and professionals, encouraging the exploration of innovative solutions to chemical hazards and the promotion of safer practices in pharmacology and toxicology.